Company
PARADROMICS
Enabling Neurotechnology
Also known as Paradromics, Inc.
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Headquarters
- Austin, TX, United States
- Customers
- restoring communication and autonomy for people with motor and speech disorders
- Legal name
- Paradromics, Inc.
- paradromics.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
We are building a high-data-rate platform for exchanging information between brains and computers. Each generation of our device will open new frontiers in human-technology integration, delivering brain therapeutics today and unlocking extraordinary human potential tomorrow.
Funding snapshot
- Total raised
- $96.9MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $50.1M2023-03-21
Funding rounds
- Round, 2023
- $50.1M2023-03-21, SEC form D sold, 53 investors
- Round, 2022
- $8.9M2022-02-17, SEC form D sold, 9 investors
- Round, 2021
- $28.2M2021-01-15, SEC form D sold, 42 investors
- Round, 2019
- $1.4M2019-03-29, SEC form D sold, 6 investors
- Round, 2018
- $7.1M2018-02-27, SEC form D sold, 34 investors
- Round, 2017
- $175K2017-05-24, SEC form D sold, 2 investors
- Round, 2015
- $985K2015-08-03, SEC form D sold, 16 investors
About the company
- Status notes
- Now in FDA-authorized human clinical studies, Connexus BCI is a fully implantable, high-data-rate interface designed to translate neural intent into communication.
Products
- Hardware
- Connexus® BCI
- Web
- Connexus® BCI
Loading relationship preview